50 terminated. 50 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 50 | Terminated 50 |
| Phase 2 | 5 | Terminated 5 |
Follow Tauopathies: new trials by email Literature Review of Tauopathies trials Research Report on Tauopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD) ION269 - Alzheimer Disease, Down Syndrome | Phase 1 | Terminated | Ionis Pharmaceuticals, Inc. | 1 | 2024-12-20 | 2026-02-20 |
| Ultrasonic Neuromodulation for Treatment of Cognitive Impairment Diadem prototype - Alzheimer Disease, Dementia | Phase 1 / Phase 2 | Terminated | University of Utah | 1 | 2024-08-18 | 2025-05-25 |
| A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01 ADEL-Y01 - healty participants, Placebo - Healthy Participants, ADEL-Y01 - MCI/AD - Alzheimer Disease | Phase 1 | Terminated | Alzheimer's Disease Expert Lab (ADEL), Inc. | 42 | 2024-02-06 | 2026-04-30 |
| Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease DSPE-DOTA-Gd Liposomal Injection - Alzheimer Disease | Phase 1 | Terminated | Alzeca Biosciences, Inc. | 16 | 2022-11-09 | 2025-08-13 |
| Tricaprilin Liquid Formulation PK Study AC-1202, AC-OLE-01, AC-OLE-02 - Alzheimer Disease | Phase 1 | Terminated | Cerecin | 71 | 2021-08-31 | 2023-10-17 |
| Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease ASN51, Placebo - Alzheimer Disease | Phase 1 | Terminated | Asceneuron Pty Ltd. | 25 | 2021-06-02 | 2023-01-17 |
| MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease JNJ-40346527, Placebo - Alzheimer Disease, Mild Cognitive Impairment | Phase 1 | Terminated | University of Oxford | 2 | 2021-04-07 | 2024-05-09 |
| Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD) SNK01 - Alzheimer Disease, Neuro-Degenerative Disease | Phase 1 | Terminated | NKGen Biotech, Inc. | 10 | 2021-01-06 | 2024-03-01 |
| Oral Fecal Microbiota Transplant Feasibility Study in Alzheimer's Disease Fecal Microbiota Transplant - Alzheimer Disease | Phase 1 | Terminated | University of Wisconsin, Madison | 5 | 2019-11-14 | 2020-07-24 |
| Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study Allopregnanolone - Alzheimer Dementia | Phase 1 | Terminated | University of Arizona | 6 | 2019-10-01 | 2026-03-13 |
| PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand 11C-ER176, 11C-PIB, Positron Emission Tomography (PET) Scan - Dementia | Phase 1 | Terminated | National Institute of Mental Health (NIMH) | 13 | 2019-07-03 | 2024-05-01 |
| A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects PU-AD, Placebo - Alzheimer's Disease | Phase 1 | Terminated | Samus Therapeutics, Inc. | 40 | 2019-06-24 | 2023-04-18 |
| Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD Lu AF20513, booster vaccine - Alzheimer Disease | Phase 1 | Terminated | H. Lundbeck A/S | 3 | 2018-12-12 | 2020-02-21 |
| A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD) Lu AF20513 - Alzheimer's Disease | Phase 1 | Terminated | H. Lundbeck A/S | 18 | 2018-06-26 | 2019-11-21 |
| Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease N-hydroxy-N'-phenyl-octanediamide (Vorinostat) - Alzheimer Disease | Phase 1 | Terminated | German Center for Neurodegenerative Diseases (DZNE) | 9 | 2017-09-28 | 2024-04-10 |
| Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease Idalopirdine - Alzheimer's Disease | Phase 1 | Terminated | H. Lundbeck A/S | 3 | 2017-09-22 | 2018-04-04 |
| NP001, Alzheimer's Disease, and Blood Markers of Inflammation NP001, Placebo - Alzheimer Disease | Phase 1 | Terminated | Beau Nakamoto | 4 | 2017-09-01 | 2018-10-22 |
| Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases Memantine, Placebo - Alzheimer Disease, Battery | Phase 1 | Terminated | University Hospital, Lille | 30 | 2016-09-14 | 2026-05-05 |
| Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants TAK-071, Donepezil, TAK-071 Placebo - Alzheimer Disease, Healthy Volunteers | Phase 1 | Terminated | Takeda | 179 | 2016-05-05 | 2019-06-10 |
| Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 BIIB092 - Supranuclear Palsy, Progressive | Phase 1 | Terminated | Biogen | 47 | 2016-02-22 | 2020-05-18 |
Showing 20 of 50. Sign in to see all of them.
Alzheimer Disease (49) · Cognitive Dysfunction (6) · Dementia (6) · Brain Diseases (2) · Cognition Disorders (2) · Multiple Sclerosis (2) · Neurocognitive Disorders (2) · Neurodegenerative Diseases (2) · Parkinson Disease (2) · Central Nervous System Diseases (1) · Depression (1) · Down Syndrome (1) · Mental Disorders (1) · Nervous System Diseases (1) · Neuroinflammatory Diseases (1)
Central Nervous System Diseases (49) · Nervous System Diseases (49) · Brain Diseases (48) · Mental Disorders (48) · Neurodegenerative Diseases (48) · Neurocognitive Disorders (47) · Dementia (43) · Cognition Disorders (5) · Basal Ganglia Diseases (3) · Movement Disorders (3) · Pathological Conditions, Signs and Symptoms (3) · Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Demyelinating Autoimmune Diseases, CNS (2)
Donepezil (3) · GSK2647544 (2) · alicapistat (2) · ispronicline (2) · (2-(6-fluoro-1H-indol-3-yl)-ethyl)-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)amine (1) · 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (1) · 3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1H-indazole (1) · 6-chloro-2-(4'-iodophenyl)-3-(N,N-diethyl)imidazo(1,2-a)pyridine-3-acetamide (1) · AC-1202 (1) · Drug Interactions (1) · Escitalopram (1) · Fecal Microbiota Transplantation (1) · Immunoglobulin G (1) · Iodine-123 (1) · Isotretinoin (1)
Institute for Neurodegenerative Disorders (8) · H. Lundbeck A/S (4) · AbbVie (2) · AstraZeneca (2) · Biogen (2) · Eli Lilly and Company (2) · GlaxoSmithKline (2) · Merck Sharp & Dohme LLC (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · Alzeca Biosciences, Inc. (1) · Alzheimer's Disease Expert Lab (ADEL), Inc. (1) · Annovis Bio Inc. (1) · Asceneuron Pty Ltd. (1) · Beau Nakamoto (1) · Cerecin (1)
United States (31) · United Kingdom (5) · Finland (3) · Germany (3) · Sweden (3) · Australia (2) · France (2) · Japan (2) · Spain (2) · Austria (1) · Italy (1) · Mexico (1) · Netherlands (1) · South Korea (1)
Danna L Jennings, MD (5) · Danna Jennings, MD (3) · Nuno Mendonca, MD (2) · Alan J Lerner, MD (1) · Barbara Bendlin, PhD (1) · Barry Reisberg (1) · Beau Nakamoto, MD PhD (1) · Danna L Jennings, M.D. (1)
PMID 30052328, PMID 22766391, PMID 27582220, PMID 34389161, PMID 36281667, PMID 38567735, PMID 39939891
2014 (3), 2018 (1), 2023 (1)